Monoclonal antibody for COVID-19: Unveiling the recipe of a new cocktail

doi:10.5320/wjr.v12.i1.1

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3080)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

WORD

HTML

1262

Figures (1-2)

322

Tables (1-1)

350

Sum=2054

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

200

Download

454

Sum=654

Publishing Process of This Article

Item

Count

Browse

154

Download

218

Sum=372

May 26, 2023 (publication date) through Jun 19, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Respirology

ISSN

2218-6255

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Respirol. May 26, 2023; 12(1): 1-9
Published online May 26, 2023. doi: 10.5320/wjr.v12.i1.1

Monoclonal antibody for COVID-19: Unveiling the recipe of a new cocktail

Jyoti Bajpai, Surya Kant, Ajay Kumar Verma, Akshyaya Pradhan

Jyoti Bajpai, Surya Kant, Ajay Kumar Verma, Department ofRespiratory Medicine, King George’s Medical University, Lucknow 226003, India

Akshyaya Pradhan, Department ofCardiology, King George’s Medical University, Lucknow 226003, India

Author contributions: Bajpai J conceptualised the article design; Bajpai J, Pradhan A, and Verma AK searched the literature; Bajpai J and Pradhan A drafted the manuscript; Critical revision was conducted by Kant S, Pradhan A, and Bajpai J.

Conflict-of-interest statement: The authors declare that they have no conflicts of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Jyoti Bajpai, MD, Assistant Professor, Doctor, Department of Respiratory Medicine, King George's Medical University, E 1204 Shalimar Gallant Mahanagar, Lucknow 226003, India. jyotibajpai33@gmail.com

Received: February 3, 2023
Peer-review started: February 3, 2023
First decision: February 21, 2023
Revised: March 3, 2023
Accepted: May 8, 2023
Article in press: May 8, 2023
Published online: May 26, 2023

Core Tip

Core Tip: The coronavirus disease 2019 (COVID-19) pandemic is a severe public health emergency that necessitated the rapid development of novel medicines and viral detection technologies. Monoclonal antibodies against the receptor-binding domain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have become an important target for the creation of therapeutic antibodies. The use of antibody cocktails is anticipated to be a key component of an efficient COVID-19 treatment plan because SARS-CoV-2 has a high mutation rate, particularly when subjected to the selection pressure of aggressively applied preventive vaccinations and neutralising antibodies.